Companies /Technology

Cognex Corp

NASDAQ: CGNX Scientific & Technical Instruments
$62.97
â–² $1.25 (+2.03%) today
Markets closed · 5:00pm ET

Q3 2025 Earnings

Reported Oct 29, 2025, 4:32pm ET · SEC source
$0.33
Beat +13.79%
EPS · est. $0.29
$276.9M
Beat +5.73%
Revenue · est. $261.9M
−7.8%
Trailing market
CGNX vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−15%−10%−5%0Oct 29Oct 30report 4:32pm ETearnings−0.4%−11.4%
−15%−10%−5%0Oct 29Oct 30earnings−0.4%−11.4%
CGNX −11.4%S&P 500 −0.4%
−15%−10%−5%0Oct 29Oct 30report 4:32pm ETearnings−0.3%−11.4%
−15%−10%−5%0Oct 29Oct 30earnings−0.3%−11.4%
CGNX −11.4%NASDAQ −0.3%
−12%−6%0Oct 28Nov 6report 4:32pm ETearnings−2.3%−15.8%
−12%−6%0Oct 28Nov 6earnings−2.3%−15.8%
CGNX −15.8%S&P 500 −2.3%
−12%−6%0Oct 28Nov 6report 4:32pm ETearnings−3.6%−15.8%
−12%−6%0Oct 28Nov 6earnings−3.6%−15.8%
CGNX −15.8%NASDAQ −3.6%
−12.92%
Day of report
+0.19%
Next session
−4.28%
One week
−7.55%
30 days

S&P 500 over the same 30 days: +0.25%.

Did CGNX Beat Earnings? Q3 2025 Results

Cognex delivered a standout Q3 2025, posting adjusted diluted EPS of $0.33 against a consensus estimate of $0.29, a 13.56% beat, while revenue climbed 18.0% year over year to $276.89 million, topping the $261.89 million consensus by 5.73%. The primary engine behind the quarter was broad-based momentum across Logistics and Factory Automation, with Consumer Electronics and Packaging contributing meaningfully, alongside a one-time benefit from a commercial partnership with a medical lab automation channel partner. Operating margin expanded 750 basis points to 20.9%, and adjusted EBITDA margin reached 24.9%, the highest level since Q2 2023. Cash generation was equally compelling, with free cash flow rising 66% to $86.03 million. Institutional investors have taken note, with several funds boosting their CGNX positions ahead of the print. Looking ahead, Cognex guided Q4 2025 revenue of $230 million to $245 million, representing roughly 3% year-over-year growth at the midpoint, with adjusted EPS of $0.19 to $0.24, as the company continues to see no material tariff impact on earnings, a reassuring contrast for <a href="https://247wallst.com/investing/2025/10/27/live-earnings-will-nxp-semiconductor-soar-after-q3-results/">semiconductor peers navigating similar pressures</a>.

Key Takeaways
  • Revenue growth driven by Logistics and strength in broader Factory Automation, particularly Consumer Electronics and Packaging
  • One-time benefit from commercial partnership with a medical lab automation channel partner contributed approximately $13 million in incremental revenue
  • Disciplined cost management drove adjusted operating expenses flat year over year; declined 2% on constant-currency basis
  • Operating margin expanded 750 basis points year over year to 20.9%
  • Adjusted EBITDA margin of 24.9% was highest level since Q2 2023
  • Adjusted diluted EPS growth of 69% year over year, fifth consecutive quarter of growth

“I'm pleased to report Q3 was another strong quarter for Cognex. We delivered outstanding financial results, which reflect our commitment to profitable growth and disciplined execution. At the same time, we remain focused on advancing our strategic objective: to be the leading provider of AI technology for industrial machine vision. Additionally, we continued to execute our salesforce transformation, acquiring new customers in underpenetrated verticals such as Packaging, using our easy-to-use, AI-enabled products.”

Cognex CEO, on the earnings call

Forward Guidance & Outlook

For Q4 2025, Cognex guides revenue of $230 million to $245 million, representing approximately 3% year-over-year growth at the midpoint. Adjusted EBITDA margin is expected in the range of 17.0% to 20.0%, compared to 18.5% in Q4 2024 (flat at midpoint). Adjusted EPS (diluted) is guided at $0.19 to $0.24, representing approximately 7.5% year-over-year growth at the midpoint versus $0.20 in Q4 2024. The company continues to expect no material impact on adjusted earnings per share or adjusted EBITDA margin from tariffs.

CGNX YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$80.0M$160.0M$240.0M$234.7M$276.9MRevenue$159.4M$187.3MGross Profit$31.6M$57.8MOperating Income$29.6M$17.7MNet Income
$0$80.0M$160.0M$240.0MRevenueGross ProfitOperating IncomeNet Income

Figures from SEC filings and company reports. Not investment advice.